Evidence map›Paper›PMID 41899557›Full record

ArticleCancers2026

Response-Adapted Benefit of Postoperative Adjuvant Therapy Following Neoadjuvant Treatment in Resectable NSCLC: A Single-Center Retrospective Cohort Study.

Yanbo Wang, Weiran Zhang, Xin Wang, Han Zhang, Qiuqiao Mu, Jianyu Wang, Qingsheng Liu, Guotai Wang, Xin Li, Daqiang Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanbo WangClinical School of Thoracic, Tianjin Medical University, Tianjin 300070, China.
Weiran ZhangChest Hospital, Tianjin University, Tianjin 300222, China.
Xin WangDepartment of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300222, China.
Han ZhangChest Hospital, Tianjin University, Tianjin 300222, China.ORCID 0009-0009-8277-0546
Qiuqiao MuClinical School of Thoracic, Tianjin Medical University, Tianjin 300070, China.
Jianyu WangClinical School of Thoracic, Tianjin Medical University, Tianjin 300070, China.
Qingsheng LiuClinical School of Thoracic, Tianjin Medical University, Tianjin 300070, China.
Guotai WangClinical School of Thoracic, Tianjin Medical University, Tianjin 300070, China.
Xin LiChest Hospital, Tianjin University, Tianjin 300222, China.ORCID 0009-0006-9139-195X
Daqiang SunDepartment of Thoracic Surgery, Tianjin Chest Hospital, Tianjin 300222, China.ORCID 0009-0000-6602-357X

Funding

International Science and Technology Innovation Cooperation Program under the National Key R&D Program of China No. 25YFGKHZ00180Noncommunicable Chronic Diseases-National Science and Technology Major Project No. 2025ZD0548500Tianjin Jinnan District Science and Technology Program 20220106Tianjin Key Medical Discipline Construction Project No. TJYXZDXK-3-031CTianjin Municipal Health Commission General Program No. TJWJ2023QN064
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvant therapyevent-free survivalmajor pathological responseneoadjuvant chemoimmunotherapyNSCLCresponse-adapted strategy

Identifiers

PMID41899557
PMCPMC13025113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.